Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile (Q33370478)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

Hans-Peter Lipp

2

object named as

Hans-Peter Lipp

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Jörg T Hartmann

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

209-230

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Effects of St. John's wort on irinotecan metabolism

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629030-00005

21 January 2018

St. John's Wort: more implications for cancer patients

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629030-00005

21 January 2018

A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629030-00005

21 January 2018

Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629030-00005

21 January 2018

International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629030-00005

21 January 2018

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629030-00005

21 January 2018

Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) acc

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased teniposide clearance with concomitant anticonvulsant therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel formulation as a cause of ethanol intoxication

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DNA topoisomerase targeting drugs: mechanisms of action and perspectives

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics of topotecan

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinical pharmacology of etoposide: an update

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypersensitivity reactions to etoposide. A case report and review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VM-26 (teniposide)-induced hypersensitivity and degranulation of basophils in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoposide kinetics in patients with obstructive jaundice

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DNA topoisomerase II in therapy-related acute promyelocytic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Control of irinotecan-induced diarrhea by octreotide after loperamide failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Altered irinotecan metabolism in a patient receiving phenytoin

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, [...]

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacologic study of topotecan in patients with impaired renal function

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CPT-11-induced cholinergic effects in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The podophyllotoxin derivatives VP16-213 and VM26.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recommended guidelines for the treatment of cancer treatment-induced diarrhea

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of etoposide phosphate

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacology of camptothecins.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Absolute bioavailability and pharmacokinetics of oral teniposide

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topoisomerase II inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan (CPT-11) metabolism and disposition in cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individual adaptive dosing of topotecan in ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute hypotensive reaction to etoposide with successful rechallenge: case report and review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of irinotecan metabolism by ketoconazole

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in the clearance of total and unbound etoposide in patients with liver dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An overview of the clinical pharmacology of topotecan

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gender-dependent pharmacokinetics of topotecan in adult patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of phenytoin on the disposition of irinotecan: a case report

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypersensitivity reactions to etoposide

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinical pharmacology of etoposide and teniposide

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and pharmacokinetic overview of parenteral etoposide phosphate

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of activated charcoal to prevent irinotecan-induced diarrhea

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stevens-Johnson syndrome associated with etoposide therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan: a new antineoplastic agent for the management of colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disposition of total and unbound etoposide following high-dose therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topoisomerase I inhibitors: review and update

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intrathecal administration of topotecan in nonhuman primates

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoposide protein binding in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insights into the pharmacokinetics and pharmacodynamics of irinotecan

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cutaneous toxicities of cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topoisomerase II inhibitor-related acute myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetics of total and unbound etoposide.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gilbert disease and type I and II Crigler-Najjar syndrome due to mutations in the same UGT1A1 gene locus

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urinary and fecal excretion of topotecan in patients with malignant solid tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of dose on the bioavailability of oral etoposide.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kinetics and regulation of cytochrome P450-mediated etoposide metabolism.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxic effect of different camptothecin formulations on human colon carcinoma in vitro.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoposide: four decades of development of a topoisomerase II inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoposide: twenty years later.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypersensitivity reactions

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoposide dosage and pharmacodynamics

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of irinotecan plus5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16)

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic considerations in the treatment of inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Camptothecins: from bench research to hospital wards.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Penetration of etoposide into human malignant brain tumors after intravenous and oral administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamic modeling of prolonged administration of etoposide.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic optimisation of treatment with oral etoposide.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trials with the topoisomerase I inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Secondary acute myelogenous leukemia following safe exposure to etoposide

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The significance of the sequence of administration of topotecan and etoposide

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topotecan: what dose, what schedule, what route?

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bioavailability of low-dose oral etoposide

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Mutagenicity tests of etoposide and teniposide]

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung

1 reference

https://pubmed.ncbi.nlm.nih.gov/16524321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00002018-200629030-00005

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33370478&oldid=2195293874"